These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 18480003)

  • 21. Pharmacogenetics of coumarinic oral anticoagulants.
    Manolopoulos VG; Ragia G; Tavridou A
    Pharmacogenomics; 2010 Apr; 11(4):493-6. PubMed ID: 20350128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Warfarin pharmacogenomics in children.
    Vear SI; Stein CM; Ho RH
    Pediatr Blood Cancer; 2013 Sep; 60(9):1402-7. PubMed ID: 23682017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of assay systems for warfarin-related CYP2C9 and VKORC1 genotyping.
    Maurice CB; Barua PK; Simses D; Smith P; Howe JG; Stack G
    Clin Chim Acta; 2010 Jul; 411(13-14):947-54. PubMed ID: 20226775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Building individualized medicine: prevention of adverse reactions to warfarin therapy.
    Krynetskiy E; McDonnell P
    J Pharmacol Exp Ther; 2007 Aug; 322(2):427-34. PubMed ID: 17496169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New allele-specific real-time PCR system for warfarin dose genotyping equipped with an automatic interpretative function that allows rapid, accurate, and user-friendly reporting in clinical laboratories.
    Kim S; Lee HW; Lee W; Um TH; Cho CR; Chun S; Min WK
    Thromb Res; 2012 Jul; 130(1):104-9. PubMed ID: 21911247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.
    Oldenburg J; Bevans CG; Fregin A; Geisen C; Müller-Reible C; Watzka M
    Thromb Haemost; 2007 Sep; 98(3):570-8. PubMed ID: 17849045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy].
    Siguret V
    Pathol Biol (Paris); 2007 Jul; 55(6):295-8. PubMed ID: 17611042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid melting curve analysis for genetic variants that underlie inter-individual variability in stable warfarin dosing.
    Carlquist JF; McKinney JT; Nicholas ZP; Clark JL; Kahn SF; Horne BD; Muhlestein JB; May HT; Anderson JL
    J Thromb Thrombolysis; 2008 Aug; 26(1):1-7. PubMed ID: 17661181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.
    Anderson JL; Horne BD; Stevens SM; Grove AS; Barton S; Nicholas ZP; Kahn SF; May HT; Samuelson KM; Muhlestein JB; Carlquist JF;
    Circulation; 2007 Nov; 116(22):2563-70. PubMed ID: 17989110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic pharmacogenetic models in anticoagulation therapy.
    Bon Homme M; Reynolds KK; Valdes R; Linder MW
    Clin Lab Med; 2008 Dec; 28(4):539-52. PubMed ID: 19059061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic influences on the response to warfarin.
    Kamali F
    Curr Opin Hematol; 2006 Sep; 13(5):357-61. PubMed ID: 16888441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin.
    Flockhart DA; O'Kane D; Williams MS; Watson MS; Flockhart DA; Gage B; Gandolfi R; King R; Lyon E; Nussbaum R; O'Kane D; Schulman K; Veenstra D; Williams MS; Watson MS;
    Genet Med; 2008 Feb; 10(2):139-50. PubMed ID: 18281922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients.
    Perini JA; Struchiner CJ; Silva-Assunção E; Santana IS; Rangel F; Ojopi EB; Dias-Neto E; Suarez-Kurtz G
    Clin Pharmacol Ther; 2008 Dec; 84(6):722-8. PubMed ID: 18754001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenomic considerations for customizing warfarin therapy in the orthopedic patient.
    Rhee S; Walsh K; Lewis D; Davis G; Smith KM
    Orthopedics; 2010 Nov; 33(11):828. PubMed ID: 21053849
    [No Abstract]   [Full Text] [Related]  

  • 35. Warfarin dose requirement for patients with both VKORC1 3673A/A and CYP2C9*3/*3 genotypes.
    Fukuda T; Tanabe T; Ohno M; Tougou K; Fujio Y; Azuma J; Yamamoto I; Takeda A
    Clin Pharmacol Ther; 2006 Nov; 80(5):553-4. PubMed ID: 17112813
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacogenetics of warfarin: current status and future challenges.
    Wadelius M; Pirmohamed M
    Pharmacogenomics J; 2007 Apr; 7(2):99-111. PubMed ID: 16983400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmocogenomics of warfarin: closing in on personalized medicine.
    Rettie AE; Tai G
    Mol Interv; 2006 Aug; 6(4):223-7. PubMed ID: 16960144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacogenetics of oral anticoagulants: individualized drug treatment for more efficacy and safety].
    Loriot MA; Beaune P
    Rev Prat; 2007 Jun; 57(12):1281-6. PubMed ID: 17717937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin.
    Vecsler M; Loebstein R; Almog S; Kurnik D; Goldman B; Halkin H; Gak E
    Thromb Haemost; 2006 Feb; 95(2):205-11. PubMed ID: 16493479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacogenetics of warfarin].
    Kessler P
    Vnitr Lek; 2006 Mar; 52 Suppl 1():31-4. PubMed ID: 16637447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.